Studie 1 (studie 11213) var et fase III, multicenter, randomiseret, dobbeltblind, placebo- kontrolleret studie med 903 patienter.
Study 1 (study 11213) was a Phase III, multi-centre, randomised, double blind, placebo-controlled study in 903 patients.